Rotavirus gastroenteritis (RV GE) is a leading cause of diarrhoea in young children. The purpose of this epidemiological surveillance was to measure the disease burden of RV GE among children <5 years of age in two regions of Switzerland, Geneva and Lucerne. One hospital and four paediatricians participated per region. The surveillance lasted from December 2006 to June 2007. The population denominator for calculation of the RV GE incidence rate was the average of the overall study population <5 years of age under surveillance during the surveillance period. At the study sites, 513 children with GE were presented. Stool sample was collected and examined in 341 cases, of which 130 were RV positive (38.1%). Informed consent to participate in the study was obtained for 113 RV positive subjects. The overall RV GE incidence rate was 0.97% in Lucerne [lower incidence interval (LCI), 0.71%; upper incidence interval (UCI), 1.2%] compared with 0.65 and in Geneva (LCI, 0.50%; UCI, 0.81%). Disease severity assessments using the Vescari score showed that the RV GE episodes were more severe in Lucerne than in Geneva (14.05 ± 3.05 vs 12.85 ± 2.87), which was confirmed by a higher hospitalisation rate in Lucerne at the study visit (82.9% vs 23.6%). More children had fever in Geneva than in Lucerne (42.9% vs 26.8%), and more children were hospitalised during the follow-up period in Geneva than in Lucerne (14.5% vs 2.5%). Genotyping of RV positive stool samples revealed that both G1 and P8 were the most prevalent types in both regions. There was a statistically significant difference in the distribution frequency of G1 between the two regions (p = 0.039). Assessment of health economic data confirmed the economic burden of RV GE episodes. In conclusion, RV GE episodes are a health burden as well as an economic burden also for the children in a developed country such as Switzerland.
Rotavirus gastroenteritis Disease burden Epidemiological study Switzerland
This is a preview of subscription content, log in to check access.
The authors would like to thank Dr. S. Itty, Dr. C. Hegi, Dr. D. Benador, Dr. C. Imobersteg, Dr. H. Schön, Dr. E. Veh and Dr. P. Trefny for participating in this study as investigators. The authors would also like to thank to GlaxoSmithKline AG, Switzerland and Sanofi Pasteur MSD AG, Switzerland, which supported the study equally.
Conflict of interest
The authors declare that they have no conflict of interest.
Berner R, Schumacher RF, Hameister S, Forster J (1999) Occurrence and impact of community-acquired and nosocomial rotavirus infections—a hospital-based study over 10 y. Acta Paediatr 88(Suppl 426):48–52CrossRefGoogle Scholar
Bucher B, Aebi C (2006) Population-based epidemiology of rotavirus hospitalisations in Switzerland. Swiss Med Wkly 136:726–731PubMedGoogle Scholar
Bundesamt für Gesundheit, Eidgenössische Kommission für Impffragen (2009) Richtlinien und Empfehlungen. Schweizerischer Impfplan, pp 1–24Google Scholar
Chan PK, Tam JS, Nelson EA et al (1998) Rotavirus infection in Hong Kong: epidemiology and estimates of disease burden. Epidemiol Infect 120:321–325CrossRefPubMedGoogle Scholar
Cook SM, Glass RI, LeBaron CW, Ho MS (1990) Global seasonality of rotavirus infections. Bull World Health Organ 68:171–177PubMedGoogle Scholar
Forster J, Hammerschmidt T (2007) Burden of acute rotavirus gastroenteritis (RV-AGE) in Germany: a comparison of federal statistics and epidemiological data. Gesundheitswesen 69:227–232CrossRefPubMedGoogle Scholar
Gabutti G, Marsella M, Lazzara C et al (2007) Epidemiology and burden of rotavirus-associated hospitalizations in Ferrara, Italy. J Prev Med Hyg 48:5–9PubMedGoogle Scholar
Gentsch JR, Glass RI, Woods P et al (1992) Identification of group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol 30:1365–1373PubMedGoogle Scholar
Giaquinto C, Van Damme P, Huet F et al (2007) Clinical consequences of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 195(Suppl 1):26–35CrossRefGoogle Scholar
Giaquinto C, Van Damme P, Huet F et al (2007) Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study. J Infect Dis 195(Suppl 1):36–44CrossRefGoogle Scholar
Gouvea V, Glass RI, Woods P et al (1990) Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stools specimens. J Clin Microbiol 28:276–282PubMedGoogle Scholar
Harris JP, Jit M, Cooper D, Edmunds WJ (2007) Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease. Vaccine 25:3962–3970CrossRefPubMedGoogle Scholar
Jit M, Edmunds WJ (2007) Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 25:3971–3979CrossRefPubMedGoogle Scholar
Kapikian AZ (2001) A rotavirus vaccine for prevention of severe diarrhoea of infants and young children: development, utilization and withdrawal. Novartis Found Symp 238:153–171 discussion 171–179CrossRefPubMedGoogle Scholar
Laubereau B, Gateau S, Ehlken B et al (1999) Rotavirus gastroenteritis in infants and children. Results of a prospective study in the area of Geneva and Basel 1997/1998 (RoMoS). Schweiz Med Wochenschr 129:1822–1830PubMedGoogle Scholar
Newall AT, Beutels P, Macartney K et al (2007) The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 25:8851–8860CrossRefPubMedGoogle Scholar
Ruuska T, Vesikari T (1990) Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 22:259–267CrossRefPubMedGoogle Scholar
Santos N, Hoshino Y (2005) Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 15:29–56CrossRefPubMedGoogle Scholar
Staat MA, Firbrother G, Edwards KM et al (2008) Delayed onset and diminished magnitude of rotavirus activity - United States, November 2007–May 2008. Morb Mortal Wkly Rep 57:697–700Google Scholar
Tucker AW, Haddix AC, Bresee JS et al (1998) Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA 279:1371–1376CrossRefPubMedGoogle Scholar
Van Damme P, Giaquinto C, Maxwell M et al (2007) Distribution of rotavirus genotypes in Europe, 2004–2005: the REVEAL Study. J Infect Dis 195(Suppl 1):S17–S25CrossRefPubMedGoogle Scholar
Widdowson MA, Meltzer MI, Zhang X et al (2007) Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 119:684–697CrossRefPubMedGoogle Scholar
Wildi-Runge S, Allemann S, Schaad UB et al (2009) A 4-year study on clinical characteristics of children hospitalized with rotavirus gastroenteritis. Eur J Pediatr (in press)Google Scholar